MIST
Milestone Pharmaceuticals Inc.2.2000
-0.1450-6.18%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
187.37MP/E (TTM)
-Basic EPS (TTM)
-0.79Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
FDA accepts CARDAMYST response
Milestone Pharmaceuticals advanced its lead drug CARDAMYST toward approval after the FDA accepted its response to a Complete Response Letter, setting a new PDUFA target of December 13, 2025, for paroxysmal supraventricular tachycardia treatment. The company bolstered its finances in July 2025 with a public offering yielding $48.7 million in net proceeds—up to $170 million if warrants exercise—extending its runway to fund commercialization if approved. Q2 2025 net loss widened to $13.0 million from $9.4 million year-over-year, driven by ramped commercial preparations. FDA approval remains uncertain.
10-Q
Q2 FY2025 results
Milestone Pharmaceuticals posted a Q2 net loss of $13.0M, up from $9.4M last year, driven by commercial expenses surging to $5.1M from $1.8M as it preps for etripamil's potential launch—yet cash climbed to $42.5M after redeeming short-term investments. Operating losses widened to $12.5M quarterly and $33.1M YTD, with EPS at $(0.20) matching the 66.4M diluted shares; no revenue yet, but the FDA accepted its CRL response in June, eyeing a December PDUFA. Debt holds steady at $55.2M in 6% convertible notes due 2029, while a July equity raise netted $48.7M to fuel the push. A July amendment extends the royalty deal deadline to year-end. Regulatory hurdles, like facility inspections, loom large.
IPO
Employees
Sector
Industry
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
CPRX
Catalyst Pharmaceuticals, Inc.
24.19+0.01
CRDL
Cardiol Therapeutics Inc.
1.04+0.01
CYTK
Cytokinetics, Incorporated
62.02-0.14
KALV
KalVista Pharmaceuticals, Inc.
15.90-1.00
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
MIRM
Mirum Pharmaceuticals, Inc.
67.05+2.95
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60